Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053819 · ClinicalTrials.gov registry record · Phase 4
Can We Miss Pigmented Lesions in Psoriasis Patients?
A Phase 4 study of Melanoma and Psoriasis, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01053819: Completed Phase 4 study of Melanoma and Psoriasis, sponsored by University of Alabama at Birmingham.
NCT01053819 is a Phase 4 study of Melanoma and Psoriasis that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01053819, a Phase 4 study of Melanoma and Psoriasis, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.
Conditions Studied
Interventions
- DRUG etanercept
Study Locations (1)
Alabama
- UAB Dermatology - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
What the finished NCT01053819 record still lists
NCT01053819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which etanercept is the first listed.
NCT01053819 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01053819 about?
NCT01053819 is a clinical study titled "Can We Miss Pigmented Lesions in Psoriasis Patients?". In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluat...
What is the current status of trial NCT01053819?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2007-09. Estimated completion is 2012-04.
What conditions does trial NCT01053819 study?
This clinical trial studies the following conditions: Melanoma, Psoriasis, Non-Melanoma Skin Cancer.
What interventions are being tested in trial NCT01053819?
The interventions under investigation include: etanercept (DRUG).
Who is sponsoring clinical trial NCT01053819?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01053819 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01053819's enrollment target sits among peer trials
6 261st of 266 higher than 4 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
COMPLETED · Phase 4
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia